Genmab — April 2014
-
Nyt phase I studie med Teprotumumab:http://www.clinicaltrials.gov/ct2/show/NCT02103283?term=Teprotumumab&rank=1
-
mange spændende smånyheder fra gen
-
nu mangler vi bare de store der virkelig kan rykke
-
men det er også river vision der starter det nye phase I - måske fordi de ser gode ting i det nuværende phase II ?
-
den skal nok lige ned og se om 200 kan holde
-
Parren declined to disclose the specific complement-enhancing mutations and mAbs that Genmab plans to use for its HexaBody platform but did note that the E345R mutation described in the study is just a prototype complement-enhancing mutation and not one of the mutations the company expects to use.
-
-
den skal bare holde sig over 200 de næste 10 handelsdag indtil PFUDA
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
